Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Sep 28, 2026
IPEX Drops -70% as De-SPAC with GOWell Closes and GOW Begins Trading on Nasdaq

IPEX Drops -70% as De-SPAC with GOWell Closes and GOW Begins Trading on Nasdaq

Key Takeaways

  • IPEX shares fell roughly 70% over 30 days, from about $10.70 on August 26, 2026, to $3.16 at the September 25, 2026 close.
  • The move accelerated as the special purpose acquisition company (SPAC) completed its business combination with GOWell Technology Limited on September 25, 2026.
  • Shareholders approved the merger on September 3, 2026, and the combined company, GOWell Energy Technology, began trading on Nasdaq under the ticker GOW on September 28, 2026.
  • Post-de-SPAC dynamics, including the removal of sponsor and representative lock-up restrictions and the loss of the trust-account net-asset-value backstop, weighed on the share price.
  • The quarterly decline is essentially the same ~70% move, concentrated almost entirely in September as the transaction neared completion.

Company Background and Positioning

Inflection Point Acquisition Corp. V (IPEX) was a blank check company, or SPAC, incorporated on May 31, 2024, in the Cayman Islands under the name Maywood Acquisition Corp. and renamed in November 2025. The company had no significant operations of its own; it was formed to effect a merger, share exchange, asset acquisition, or similar business combination. It completed its initial public offering in February 2025, raising approximately $86.25 million, and was led by principals of Inflection Point Asset Management under Chairman and CEO Michael Blitzer.

The company's designated target, GOWell Technology Limited, is a Singapore-headquartered provider of well logging technologies and distributed sensing solutions for the global energy sector. GOWell has operated for roughly two decades, maintains a patent portfolio and multi-disciplinary R&D team, and serves a diverse customer base that includes major oilfield service companies and operators across more than 50 countries. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Stock Performance Over the Past 30 Days and Quarter

Over the last 30 days, IPEX declined approximately 70%, falling from a close of $10.70 on August 26, 2026, to $3.16 at the September 25, 2026 close. The single largest move occurred on September 25, when shares fell about 58% from the prior session's close of $7.49 as the business combination formally closed.

The quarterly picture tells the same story. At the end of June 2026, IPEX traded near $10.52, close to the roughly $10.48 per-share redemption value held in the trust account. Shares remained in a narrow range near that level through much of the third quarter before a sharp, concentrated selloff in September drove the stock to $3.16, a decline of roughly 70% for the period.

Factors Behind the 30-Day Move

The dominant catalyst was the completion of IPEX's de-SPAC transaction. The proposed combination with GOWell Technology Limited, signed in October 2025 at a pro-forma enterprise value of approximately $401.4 million, was approved by Inflection Point shareholders on September 3, 2026, and closed on September 25, 2026.

Several mechanics specific to SPACs contributed to the decline. First, once the transaction closed, shares no longer carried the cash redemption backstop that had supported the price near the trust value of roughly $10.48. Second, on August 31, 2026, the parties amended the business combination agreement to terminate post-closing lock-up restrictions for the sponsors and certain representatives, making an aggregate of approximately 3,337,500 shares freely tradeable upon closing. Third, the transition to a newly combined, smaller-float operating company introduced significant volatility as holders adjusted to the post-closing share structure and to a valuation no longer anchored by the trust account.

Quarterly Performance in Context

For most of the quarter, IPEX behaved like a typical pre-deal SPAC, trading in a narrow band near its redemption value while investors awaited the outcome of the GOWell transaction. The company extended its deadline to complete a business combination into September 2026, and the registration statement on Form F-4 was declared effective by the SEC in August 2026.

The sharp repricing in September reflects the shift from a cash-shell security toward an operating company with a forward-looking equity story rather than a liquidation floor. The removal of lock-up restrictions and the completion of the merger concentrated that repricing into a short window, producing a quarterly decline of approximately 70% that mirrors the 30-day move.

What to Watch After the Merger

Following the September 25, 2026 closing, the combined company now operates as GOWell Energy Technology and trades on Nasdaq under the ticker GOW. Investors should monitor the combined company's first financial results as a public entity, including revenue and margin trends in well logging and distributed sensing, as well as how the approximately $70 million in gross PIPE proceeds are deployed toward growth initiatives and working capital.

Other factors to watch include demand conditions across the oilfield services and energy markets, the company's ability to meet earnout-related EBITDA targets, competitive pressures in the wireline logging segment, and the liquidity and ownership dynamics that follow a de-SPAC with a relatively small float. These considerations reflect forward-looking risk factors rather than a projection of future performance. From what I see, this transition period often brings heightened volatility.

Exploring Tickeron’s AI Trading Bots

In my research process, I often turn to Tickeron’s AI Trading Bots to get a sense of algorithmic positioning across different strategies. The platform offers a range of approaches from short-term technical setups to longer-horizon trend models, allowing me to cross-check my own analysis with data-driven signals. Investors can explore these tools to see how bots are positioned in the current market environment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IPEX

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


IPEX's Stochastic Oscillator is staying in oversold zone for 2 days

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +25.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where IPEX advanced for three days, in 2 of 24 cases, the price rose further within the following month. The odds of a continued upward trend are 8%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IPEX as a result. In 4 of 26 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 15%.

The Moving Average Convergence Divergence Histogram (MACD) for IPEX turned negative on September 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 28 similar instances when the indicator turned negative. In 2 of the 28 cases the stock turned lower in the days that followed. This puts the odds of success at 7%.

IPEX moved below its 50-day moving average on September 16, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IPEX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 7%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. IPEX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.449) is normal, around the industry mean (126.658). IPEX has a moderately high P/E Ratio (1052.000) as compared to the industry average of (172.807). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (15.932). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (1.790).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IPEX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.

Industry description

Financial conglomerates usually encompass a wide range of financial services including (not necessarily limited to) investment banking, insurance, capital raising/underwriting, trading of financial securities, investment advisory services, wealth management of high net-worth individuals, and retail banking. Think Citigroup, American Express Company, ING Group.

Market Cap

The average market capitalization across the Financial Conglomerates Industry is 262.1M. The market cap for tickers in the group ranges from 1.85 to 590.24B. IMAQU holds the highest valuation in this group at 590.24B. The lowest valued company is ATMVU at 1.85.

High and low price notable news

The average weekly price growth across all stocks in the Financial Conglomerates Industry was -1%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 3%. RFAIU experienced the highest price growth at 9%, while IPEXU experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Financial Conglomerates Industry was -46%. For the same stocks of the Industry, the average monthly volume growth was -20% and the average quarterly volume growth was -61%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 34
P/E Growth Rating: 88
Price Growth Rating: 54
SMR Rating: 96
Profit Risk Rating: 99
Seasonality Score: 2 (-100 ... +100)
View a ticker or compare two or three
IPEX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry FinancialConglomerates

Industry
N/A
Address
167 Madison Avenue, No. 1017
Phone
+1 212 476-6908
Employees
3
Web
N/A
Interact to see
Advertisement
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.
Shares of GSAT are surging approximately +15% intraday on March 25, 2026, following a prior session close of $61.09. The primary catalyst is a fresh analyst note from Scotiabank highlighting Globalstar's direct-to-device satellite connectivity bypassing cellular towers — most notably in Mexico — reinforcing the company's next-generation infrastructure thesis.
Shares of ADMA are declining approximately 12% in Wednesday's session, extending a steep two-day selloff. The primary catalyst is a short-seller research report published by Culper Research on March 24, 2026, alleging that ADMA engaged in channel stuffing to artificially inflate revenue growth.
Honeywell International (HON) and TransDigm Group (TDG) are prominent players in the aerospace and industrials sector, benefiting from rising air travel demand, defense spending, and aftermarket services. This stock comparison evaluates their business models, recent performance, and market positioning to help traders and investors assess relative strengths in the current environment. With global aviation recovery and geopolitical tensions supporting sector tailwinds, professionals seeking exposure to aerospace growth versus diversified industrials stability will find these insights relevant for portfolio decisions and relative performance analysis.
PL shares are surging approximately +15% in Wednesday's session, trading near $35.89, pushing back toward the stock's 52-week high of $36.28 set on March 20, 2026. Primary catalyst: Continued momentum from a blockbuster Q4 fiscal 2026 earnings report delivered March 19, which sent revenue 41% higher year-over-year to $86.8 million, well above the $78 million Wall Street consensus.
ASTS shares surged approximately +11.00% in active intraday trading on March 25, 2026, moving from a prior close of $86.98 to approximately $96.55. The primary driver is a broad space sector rally fueled by renewed SpaceX IPO speculation, lifting satellite and space-related equities across the board.
FUBO shares are set to open about 12% lower in Wednesday’s premarket session after closing the prior day at roughly $12.02. The decline follows a strong multi-week rally powered by balance-sheet news, including the repurchase of $140.2 million of 2026 convertible notes and improving profitability trends.
One & One Green Technologies Inc. (YDDL) shares are indicated down about 13% in Wednesday’s premarket session after closing the prior regular session at $12.00. The stock had just surged 15.6% in the latest completed session, jumping from a prior close of $10.38 to $12.00, leaving it vulnerable to swift profit‑taking and volatility.
AVXL shares are indicated down about 33% in Wednesday’s premarket session, after closing the prior regular session at $4.19. The slide follows a recent drop triggered by a wider‑than‑expected fourth‑quarter loss and ongoing questions about the company’s late‑stage neurology pipeline.
AUGO shares are trading roughly 9% higher in Wednesday action, moving from a prior close of $66.42 to around $72.40 intraday. The stock’s advance extends a powerful year-long rally underpinned by record 2025 production, surging Adjusted EBITDA, and a recently declared cash dividend of $0.66 per share.
NAVN shares are surging approximately +25% in premarket trading on March 26, 2026, following a blockbuster earnings report released after the close of the prior session. Primary catalyst: Q4 fiscal year 2026 results delivered a significant beat — revenue of $178 million rose 35% year-over-year, surpassing analyst forecasts by nearly 10%.
OLPX surged approximately +50.38% in premarket trading on March 26, 2026, from a previous close of $1.33 to approximately $2.00, with an intraday premarket high of $2.03. The primary catalyst is a definitive acquisition agreement by German consumer goods giant Henkel AG to purchase Olaplex for $2.06 per share in an all-cash deal, valuing the company at approximately $1.4 billion.
TASK shares are down approximately -36% in premarket trading on March 26, 2026, the stock's official ex-dividend date for its special $3.65 per share cash dividend. The $3.65 special cash dividend — exceeding 25% of the stock's pre-ex-div market value — triggered a mandatory Nasdaq-prescribed price adjustment on today's open.
MLKN shares are down approximately 18.90% in premarket trading on March 26, 2026, falling to $15.70 from the prior session's close of $19.36. The primary catalyst is a double miss on both earnings and revenue in the company's fiscal Q3 2026 report released after the close on March 25.
Wave Life Sciences (WVE) shares are tumbling approximately 51% in premarket trading on March 26, 2026, from a prior close of $12.30 to approximately $6.03. The primary catalyst is the release of highly anticipated INLIGHT Phase 1 clinical data for WVE-007, the company's investigational INHBE GalNAc-siRNA obesity treatment, with results falling materially short of investor expectations.
APP is trading approximately 6% lower in premarket trading on March 26, 2026, extending a multi-session losing streak. The prior regular-session close (March 25, 2026) stood at $435.91, itself already down 5.02% from the day before, making the premarket slide a continuation of accelerating selling pressure.
KOD shares surged approximately +50% in premarket trading on Thursday, March 26, 2026, from a prior closing price of $22.75 to approximately $34.13. The primary catalyst is a landmark readout: the GLOW2 Phase 3 trial of Zenkuda (tarcocimab tedromer) in diabetic retinopathy met its primary endpoint with overwhelming statistical significance.